Adcendo Appoints Dominik Mumberg, PhD, as Chief Scientific Officer

May 3, 2022

Brings in-depth R&D expertise in oncology, including ADCs, targeted radiotherapies, immunooncology and small moleculesAdcendo building a world class team of experienced biotech & pharma executives and renowned leaders in the ADC field Copenhagen, Denmark, May...

Data Presentation on uPARAP targeting ADCs in Osteosarcoma PDX Models at the 2022 AACR Annual Meeting

Apr 12, 2022

The poster presentation highlights the preclinical evaluation of several of Adcendo´s ADC candidates for the treatment of osteosarcoma Copenhagen, Denmark, April 11th, 2022 – Adcendo ApS (“Adcendo”), a biotech company focused on the development of...

Adcendo Further Strengthens Management Team and Scientific Advisory Board with Appointment of International ADC Leaders

Dec 1, 2021

Building the team with experienced biotech experts and renowned leaders in the ADC fieldUnderscores company’s commitment to progressing lead program on novel ADC target uPARAP Copenhagen, Denmark, December 1st, 2021 – Adcendo, a biotech company focused on the...

The Collagen Receptor uPARAP in Malignant Mesothelioma: A Potential Diagnostic Marker and Therapeutic Target (2021)

Oct 23, 2021

Adcendo Appoints Michael Pehl as Chief Executive Officer

Jul 6, 2021

Experienced Industry Leader with successful Oncology, Immunotherapy & ADC Development Track Record Adcendo, a biotech company developing innovative antibody-drug conjugates (ADCs) for the treatment of underserved cancers, announces today the appointment of Michael...